Summary.-Carrageenan (Cg) was tested for its effects on the growth of, and immunity to, 2 methylcholanthrene-induced syngeneic murine fibrosarcomas (HI and H2). The tumours were found not to share major tumour-specific transplantation antigens. H2 appeared more immunogenic than HI. In contrast to HI, immunity induced by H2 was not affected by Cg, nor was its growth in Cg-treated normal mice augmented. We propose that TBS does not inhibit CMI in vivo provided that macrophages remain functional, but may do so when macrophages are rendered defective by antimacrophage agents or by products of neoplastic cells. Increasing the levels of specific effector cells can over-ride the inhibiting effects of TBS, even when defective macrophages are present.
We propose that TBS does not inhibit CMI in vivo provided that macrophages remain functional, but may do so when macrophages are rendered defective by antimacrophage agents or by products of neoplastic cells. Increasing the levels of specific effector cells can over-ride the inhibiting effects of TBS, even when defective macrophages are present.
TUMOUR-REJECTION IMMUNITY is a complex process in which many components of the lymphoreticular system interact, but the principal effector cells appear to be T lymphocytes and macrophages (Alexander et al., 1972; Evans & Alexander, 1971; Fink, 1976) . T lymphocytes separated from tumours have been shown to have specific anti-tumour activity (Gillespie et al., 1977; Plata & Sordat, 1977) , and macrophages recovered from tumours appear to be either cytostatic (Evans, 1973; Haskill et al., 1975; Von Loveran & den Otter, 1974) or cytocidal (Russell et al., 1976) .
Evidence in support of a role for macrophage-like cells in amplifying lymphocyte killing has been obtained from studies both in vitro and in vivo (Simes et al., 1975) . More direct evidence for the participation of macrophages in tumour rejection has been obtained by attempts to ablate macrophages in vivo by a variety of agents including carrageenan, silica or trypan blue (Zarling & Trevethia, 1973; Keller, 1976; Kripke et al., 1977; Thomson & Fowler, 1977; . Treatment by these agents, known to diminish the functional capacity of macrophages in vitro, led to markedly augmented growth of many tumours in normal animals.
The aim of the present investigation was to establish whether 2 chemicallyinduced syngeneic tumours produce specific immunity after either the administration of mitomycin-C-treated tumour cells (Benjamini et al., 1977) or the surgical removal of tumour isografts, and to determine whether the administration of carrageenan altered the immunity induced by either of the above methods.
MATERIALS AND METHODS
Animals.-Male mice (8-12 weeks old) of the highly inbred CBA/H/WEH1 strain were used. Their origin and maintenance have been discussed previously (Basten et al., 1974) .
Tumours.-Two syngeneic methylcholanthrene-induced fibrosarcomas designated HI and H2 were used. Tumour-cell suspensions were prepared from freshly excised tumours by gently disaggregating tumour fragments in 5-10 ml of 0.1% pronase in Dulbeccomodified Eagles' medium (DME) as described previously (Kearney & Nelson, 1973) . The cell suspension obtained was washed x3 in DME containing 15% foetal calf serum (FCS). Cells were finally suspended in serumfree medium and the the viability determined by trypan-blue exclusion. Viable tumour-cell suspensions in serum-free medium were adjusted to the appropriate concentration indicated for particular experiments. Viable tumour cells were injected s.c. in a volume of 0-2 ml along the midline of the abdominal wall. At daily intervals, usually after the 4th day, the smallest and largest diameters of the tumours were measured (to the nearest 0-1 mm) by a Schnelltaster dial gauge (Kearney & Nelson, 1973) or by vernier calipers. The tumour diameter was expressed as the average of both diameters, and corrected for average thickness of the uninjected mouse skin-fold of the abdominal wall. The mean tumour diameters are rerecorded with their standard errors.
Excision and rechallenge assays of tumour immunity.-Mice were immunized with living tumour inoculated s.c. in the flank, followed by tumour excision. The faster-growing HI tumour was inoculated in a dose of 106 cells, which developed 10-15mm sarcomas within 10-12 days, when they were excised under ether anaesthesia. The slower-growing H2 tumour, in a dose of 107 cells, grew to about the same size within 12-14 days, when they were similarly excised. Six weeks after surgical excision, these mice and control mice were challenged s.c. along the midline of the abdominal wall with the appropriate challenge dose as indicated in the particular experiments.
Preparation of mitomycin-C-treated tumour cells (MCT cells).-Tumour cells obtained by incubation with 0-1% pronase in DME medium were washed x3 in DME medium with 20% FCS. Mitomycin C (MC) ( Table I. (NMS) was pooled from 20-30 donor mice. In this experiment MCT-H1-immunized mice were injected i.p. with 0 9 ml of TBS or 0*9 ml of NMS on the 14th day after immunization. Unimmunized agematched controls received the same treatment. One hour after receiving serum, all animals were injected s.c. with 05 x 105 HI cells along the midline of the abdominal wall. Results are shown in Table  II and Fig. 7 , where it is seen that TBS appeared to have no effect on the growth of the tumour in normal mice, and no effect on the ability of immunized mice to express resistance. Table II (q.v.) . Lambda carrageenan; 2 mg injected i.p. between Days 10 and 14 after MCT-H1 inoculation. TBS collected from donor mice 5, 6, 7, and 8 days after inoculation with 3 x 106 HI cells. Recipient mice were injected i.p. 14 days after MCT-HI inoculation, and 1 h before challenge with 0-5 x 105 Hi tumour cells.
treatment with Cg together with administration of TBS, although either of these treatments alone had no effect (Table III) .
In Tables II and III , the tumours which occurred in immune mice treated with NMS were significantly smaller than those in normal mice treated with NMS.
DISCUSSION
Cg has many biological effects (Di Rosa, 1972) including inhibition of blood coagulation (Anderson & Duncan, 1965) and the complement system (Davies, 1965) . Cg also has the ability to interfere with antibody reactions in vivo (Ishizaka et al., 1977) . In addition, the substance is toxic for macrophages in vttro (Catanzaro et al., 1971) and in vivo . Its augmenting effect upon syngeneic tumours has been reported by several workers (Keller, 1976; Thomson & Fowler, 1977; . Keller (1976) suggested that the augmented tumour growth could be explained by a diminished period of macrophage function leading to successful tumour implantation and initiation of progressive growth. In support of this interpretation, Keller (1976) found that the augmenting effects of C(g (and silica) on tumour growth were reversed by the macrophage-stabilizing agent poly -2 -vinylpyridine N -oxide (PVNO) a substance known to reverse the immunosuppressive effect of silica and Cg (Rios & Simmons, 1972) . However, Keller (1976) observed that tumour growth could also be increased by a growthpromoting agent released from damaged macrophages.
In the present experiments, Cg greatly increased the growth of the low-immunogenic HI tumour in mice immunized by tumour excision and then treated with Cg before secondary challenge. In direct contrast, however, Cg had no effect on the same tumour when inoculated into mice immunized by MCT-H1 cells. This difference must be due to the differences in the type of immunity induced by tumour excision and MCT inoculation. Evidence by Benjamini et al. (1977) and Wu & Kearney (submitted for publication) revealed that the development of MCTinduced immunity was paralleled by the development of specific cell-mediated cytotoxicity without the formation of detectable anti-tumour antibodies. On the other hand, specific immunity acquired by tumour excision is mediated by both cytotoxic cells (Belehradek et al., 1972) and antibody (Pilch & Riggins, 1966) . By using a modification of the method described by Brown et al. (1977) , sera from Hf1 tumour-bearing mice and from mice immunized by tumour excision were found to possess specific antibody to the HI tumour (Kearney, to be published). However, similar antibody activity could not be found in sera of mice immunized by MCT-H 1 cells. Therefore, in addition to the magnitude of the immune responses, a major factor which could also determine whether tumour growth is enhanced or not in immune mice pretreated with Cg is whether antibody accompanies the cellmediated response.
The in vitro cell-mediated response to the HI tumour is feeble, and depends upon the amplification of the weak cytotoxic Fffect of the T-cell component by macrophage-like cells . The present experiments show that the immunity acquired in vivo by either surgical removal of the H 1 tumour or MCT treatment is also weak. The effect of Cg on macrophages could account for the even lower resistance found in mice whose primary isograft had been removed. The macrophage-stabilizing properties of PVP (Hochschild, 1973) largely reversed the augmenting effect of Cg in mice immunized by HI-tumour excision. The situation is clearly different in MCT-immunized mice, in which the immunity is not abrogated by Cg. Possibly the numbers of specific effector T cells in Cg-treated MCT-immune mice were able to control the growth of a challenge tumour inoculum in the absence of antibody without the presence of functional macrophages.
The loss of immunity in Cg-treated mice immunized by tumour excision may have been due to the inhibition of cytotoxic effector cells by a serum factor, presumably antibody, in the absence of functional macrophages.
Cg does not abolish pre-existing humoral immunity to sheep erythrocytes, but the secondary response to sheep erythrocytes in Cg-treated mice is delayed (Kearney & Orr, unpublished 
